SWITCH STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE (FTC/RPV/TAF) FIXED DOSE COMBINATION (FDC) IN HIV-1 POSITIVE ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE (FTC/RPV/TDF):